Fermentation of ginsenoside Rb1 by a probiotic mixture alleviates atopic dermatitis via synergistic effects of rare ginsenoside F2 and gut microbiota-derived 12-ketolithocholic acid in mice
- 1Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, China.
- 2College of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
- 3Taizhou Medical City Guokehuawu Bio-Pharm Co., Ltd, Taizhou, 225300, China.
Abstract
Atopic Dermatitis (AD) is a chronic, relapsing inflammatory skin disorder with increasing global incidence. Emerging evidence highlights a strong association between AD and gut dysbiosis. In this context, compounds from Chinese herbal medicine (CHM), such as ginsenosides, have gained attention for their anti-inflammatory and immunomodulatory properties. However, the poor bioavailability of major ginsenosides limits their therapeutic effectiveness. Recent advances in probiotic-based herbal medicine fermentation suggest that, in addition to manipulation of gut dysbiosis, probiotics also show promising potential for enhancing the bioconversion of major ginsenosides into rare ginsenosides. The objective of this study was to determine whether probiotic-fermented ginsenoside Rb1 broth (Rb1FB) could alleviate 2,4-dinitrochlorobenzene (DNCB) atopic dermatitis-like disease and to investigate the associated gut–skin mechanisms. Rb1FB improved visible skin lesions and reduced dermatitis severity and significantly reduced epidermal thickening, dermal mast-cell infiltration, serum immunoglobulin E (IgE) and tumor necrosis factor-α (TNF-α) in AD mice. Rb1FB also increased gut microbial richness and diversity, enriched Bacteroides , increased fecal 12-ketolithocholic acid (12-KLCA), and enhanced systemic exposure to the rare ginsenoside F2. Therefore, the principal biological outcomes were improvements in the clinical-like, histopathological, allergic, and inflammatory features of AD, while the microbiome, metabolomic, and serum ginsenoside findings provided potential mechanistic explanations. Methods: Probiotic strains Lactiplantibacillus plantarum DMU22441 , Lactobacillus acidophilus DMU22440 , and Lactiplantibacillus plantarum DMU22439 were screened for Rb1 utilization, and their fermentation conditions for maximum release of rare ginsenosides were optimized to prepare Rb1FB. A DNCB-induced AD mouse model was established to assess the therapeutic effects of Rb1FB. 16 S ribosomal RNA (rRNA) gene sequencing, metabolomics, transcriptomics and in vitro studies were employed to explore the mechanism of action. Results: Rb1FB significantly alleviated AD symptoms in mice, reduced serum IgE and TNF-α levels, modulated the gut microbiota, and increased systemic exposure to the rare ginsenoside F2. In TNF-α-stimulated HaCaT cells, combined treatment with F2 and gut microbiota-associated 12-KLCA produced greater suppression of selected inflammatory genes than either treatment alone and was associated with reduced NUAK family kinase 2 (NUAK2). Conclusion: Rb1FB modulates the gut microbiota and its metabolites, enhances rare ginsenoside absorption, and alleviates AD symptoms in mice. F2 and 12-KLCA produced an enhanced combined inhibitory effect on inflammatory responses in vitro. These findings support the therapeutic potential of probiotic-fermented ginsenoside Rb1 for AD.
Related
- Ginsenoside Rb1 alleviates uterine aging via AMPK-mediated mTOR inactivation
- Ginsenoside Rd alleviates atherosclerosis by inhibiting adipocyte ferroptosis in perivascular adipose tissues
- Ginsenoside Rg1 Alleviates Chronic Obstructive Pulmonary Disease Partially Through Regulating ABCB1-Mediated Mitochondrial Dysfunction.
- In vitro iron nanoparticles modulate ginsenoside biosynthesis and trigger ROS-mediated stress response in ginseng adventitious roots.
- Tailored Covalent Organic Frameworks Enable the Encapsulation of Living Cells to Produce Rare Ginsenoside
BibTeX
@article{yuan2026fermentation,
title = {{Fermentation of ginsenoside Rb1 by a probiotic mixture alleviates atopic dermatitis via synergistic effects of rare ginsenoside F2 and gut microbiota-derived 12-ketolithocholic acid in mice}},
author = {Donglin Yuan and Bushra Walayat and Xinyi Chen and Dandan Xiang and Yu Xing and Chaoran Wang and Ming Li and Binbin Hou},
journal = {Journal of Ginseng Research},
year = {2026},
month = sep,
doi = {10.1016/j.jgr.2026.101153},
url = {https://doi.org/10.1016/j.jgr.2026.101153},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Fermentation of ginsenoside Rb1 by a probiotic mixture alleviates atopic dermatitis via synergistic effects of rare ginsenoside F2 and gut microbiota-derived 12-ketolithocholic acid in mice
AU - Donglin Yuan
AU - Bushra Walayat
AU - Xinyi Chen
AU - Dandan Xiang
AU - Yu Xing
AU - Chaoran Wang
AU - Ming Li
AU - Binbin Hou
PY - 2026
DA - 2026/09/11
JO - Journal of Ginseng Research
DO - 10.1016/j.jgr.2026.101153
UR - https://doi.org/10.1016/j.jgr.2026.101153
AB - Atopic Dermatitis (AD) is a chronic, relapsing inflammatory skin disorder with increasing global incidence. Emerging evidence highlights a strong association between AD and gut dysbiosis. In this context, compounds from Chinese herbal medicine (CHM), such as ginsenosides, have gained attention for their anti-inflammatory and immunomodulatory properties. However, the poor bioavailability of major ginsenosides limits their therapeutic effectiveness. Recent advances in probiotic-based herbal medicine fermentation suggest that, in addition to manipulation of gut dysbiosis, probiotics also show promising potential for enhancing the bioconversion of major ginsenosides into rare ginsenosides. The objective of this study was to determine whether probiotic-fermented ginsenoside Rb1 broth (Rb1FB) could alleviate 2,4-dinitrochlorobenzene (DNCB) atopic dermatitis-like disease and to investigate the associated gut–skin mechanisms. Rb1FB improved visible skin lesions and reduced dermatitis severity and significantly reduced epidermal thickening, dermal mast-cell infiltration, serum immunoglobulin E (IgE) and tumor necrosis factor-α (TNF-α) in AD mice. Rb1FB also increased gut microbial richness and diversity, enriched Bacteroides , increased fecal 12-ketolithocholic acid (12-KLCA), and enhanced systemic exposure to the rare ginsenoside F2. Therefore, the principal biological outcomes were improvements in the clinical-like, histopathological, allergic, and inflammatory features of AD, while the microbiome, metabolomic, and serum ginsenoside findings provided potential mechanistic explanations. Methods: Probiotic strains Lactiplantibacillus plantarum DMU22441 , Lactobacillus acidophilus DMU22440 , and Lactiplantibacillus plantarum DMU22439 were screened for Rb1 utilization, and their fermentation conditions for maximum release of rare ginsenosides were optimized to prepare Rb1FB. A DNCB-induced AD mouse model was established to assess the therapeutic effects of Rb1FB. 16 S ribosomal RNA (rRNA) gene sequencing, metabolomics, transcriptomics and in vitro studies were employed to explore the mechanism of action. Results: Rb1FB significantly alleviated AD symptoms in mice, reduced serum IgE and TNF-α levels, modulated the gut microbiota, and increased systemic exposure to the rare ginsenoside F2. In TNF-α-stimulated HaCaT cells, combined treatment with F2 and gut microbiota-associated 12-KLCA produced greater suppression of selected inflammatory genes than either treatment alone and was associated with reduced NUAK family kinase 2 (NUAK2). Conclusion: Rb1FB modulates the gut microbiota and its metabolites, enhances rare ginsenoside absorption, and alleviates AD symptoms in mice. F2 and 12-KLCA produced an enhanced combined inhibitory effect on inflammatory responses in vitro. These findings support the therapeutic potential of probiotic-fermented ginsenoside Rb1 for AD.
SN - 1226-8453
SN - 2093-4947
ER -